These findings contrast those for genetically predicted HMGCR inhibition, which corroborated clinical trial data to support the effects of statins on increasing T2DM risk, waist-to-hip ratio, HbA1c and BMI. The gene discussed is HMGCR; the disease is type 2 diabetes mellitus.